Comparative Pharmacology
Head-to-head clinical analysis: DARVON N versus TRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON N versus TRAL.
DARVON-N vs TRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist that produces analgesia by binding to opioid receptors in the central nervous system, altering the perception of and response to pain. Its metabolite norpropoxyphene has local anesthetic and sodium channel blocking effects, which may contribute to cardiac toxicity.
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
100 mg orally every 4 hours as needed for pain; maximum 600 mg per day.
10 mg intravenously once daily
None Documented
None Documented
Clinical Note
moderateSertraline + Desmopressin
"The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin."
Clinical Note
moderateSertraline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Cyclosporine
Propoxyphene: 6-12 hours; norpropoxyphene: 30-36 hours. Accumulation of norpropoxyphene on repeated dosing increases risk of toxicity.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for CrCl <60 mL/min.
Primarily renal (approximately 70% as unchanged drug and glucuronide conjugates); minor biliary/fecal elimination (25-30%).
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The metabolism of Cyclosporine can be decreased when combined with Sertraline."